Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASAP Trial: Remission Induction vs Disease Control in Relapsed/Refractory AML
NCT02461537Phase 3Completed
- Sponsor
- DKMS
- Start
- Sep 2015
- Primary completion
- Apr 2022
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cytarabine and mitoxantrone in acute myeloid leukemia (AML) (2 arms), sponsored by DKMS. Primary endpoint: Disease-free survival at Day 56. Started Sep 2015; status: completed.
02
Drugs
cytarabinemitoxantrone
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02461537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02461537.